Data from both randomized trials suggest that ATDM-supported diabetes care can improve self-care, glycemic control, and patient-centered outcomes. Among participants in the county clinic trial, outcome data were collected at 12-months for 248 (89%) of all enrollees. Compared to the usual care group, intervention patients at follow-up reported more frequent glucose self-monitoring, foot inspection, and weight monitoring, and fewer medication adherence problems (all p < .03).48 The publication is included in Appendix 1. Mean follow-up HbA1c values among intervention and control patients were 8.1% and 8.4% (p = .01), and more than twice as many intervention patients were within the normal range for HbA1c (p =.04). Intervention patients also had lower mean serum glucose levels (180mg/dl versus 221 mg/dl) and reported better glycemic control (both p < .005). On average, intervention patients reported fewer diabetic symptoms than usual care patients (4.0 versus 5.4) (p< .0001) including fewer symptoms of hyperglycemia (p< .0005) and hypoglycemia (p < .001).